CanSino Biologics (06185.HK): MCV4 Vaccine Granted Registration Certificate in Argentina

NewTimeSpace News: On June 25, 2026, CanSino Biologics (06185.HK) released a voluntary announcement stating that its Group A, C, Y and W135 Meningococcal Conjugate Vaccine (CRM197 carrier) (MCV4, trade name: Menhyxin®) has been awarded a registration certificate by Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) of Argentina.

As stated in the announcement, Menhyxin® is the first domestically approved Group A, C, Y and W135 Meningococcal Conjugate Vaccine in China. It has been approved domestically for children aged 3 months to 6 years old (83 months), indicated for the prevention of epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroups A, C, Y and W135.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.